Werewolf Therapeutics stock soars 120% on Ambros merger deal
Werewolf Therapeutics (NASDAQ: HOWL) shares rose 120% premarket after announcing a merger with Ambros Therapeutics and a $150M private placement. The combined company, trading as AMBX, will focus on neridronate for CRPS-1. The merger is expected to close in Q1 2027, with Ambros shareholders owning 71.7% of the new entity.
How this was made
The 30-second read
Why it matters
The merger creates a combined entity valued at roughly $500M for Ambros and $47.5M for Werewolf, with a new ticker AMBX expected post‑close.
Market read
Primary disclosure of a sizable biotech merger and capital raise, driving a 120% pre‑market rally.
What to watch
Regulatory approval of the CRPS‑1 candidate remains uncertain.
Background
The article reports a newly announced merger and private placement for Werewolf Therapeutics.
Ticker impact
Werewolf Therapeutics announced a merger with Ambros Therapeutics and a $150M private placement, sending its shares up 120% pre‑market.
Expect continued upside as the deal closes, with potential short‑term pull‑back on profit‑taking.
Deal terms are disclosed for the first time, valuation is clear, and the stock already rallied sharply on the news.
Market effects
Consolidation in the rare‑disease biotech space may spur M&A activity.
U.S. biotech sector could see a modest lift.
Limited to biotech investors; no broad market effect.
Counterpoint
Deal dilution and execution risk could pressure the stock if closing delays occur.
Key entities
- companyWerewolf Therapeutics Inc
Biotech firm announcing merger and private placement.
- companyAmbros Therapeutics Inc
Target of the merger, developer of neridronate.
